Дилатационная кардиомиопатия. Клинические рекомендации 2025

Российское кардиологическое общество (РКО), Общество специалистов по сердечной недостаточности, Российское научное медицинское общество терапевтов, Ассоциация сердечно-сосудистых хирургов России (АССХ)

Одобрено Научно-практическим Советом Минздрава Российской Федерации

1. Лебедев Д. С., Михайлов Е. Н., Неминущий Н. М. и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4600. doi:10.15829/1560-4071-2021-4600.

2. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-626. doi:10.1093/eurheartj/ehad194.

3. Harakalova M, Kummeling G, Sammani A, et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur J Heart Fail. 2015;17(5):484-93. doi:10.1002/ejhf.255.

4. Hershberger RE, Morales A. Dilated Cardiomyopathy Overview. 2007 [Updated 2018 Aug 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.

5. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013;123(1):19-26. doi:10.1172/JCI62862.

6. Japp AG, Gulati A, Cook SA, et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016;28;67(25):2996-3010. doi:10.1016/j.jacc.2016.03.590.

7. Kinnamon DD, Morales A, Bowen DJ, et al. DCM Consortium. Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study. Circ Cardiovasc Genet. 2017;10(6):e001826. doi:10.1161/CIRCGENETICS.117.001826.

8. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;16;17(9):507-22. doi:10.1038/nrg.2016.86.

9. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;22;71(20):2293-302. doi:10.1016/j.jacc.2018.03.462.

10. Noutsias M, Rohde M, Göldner K, et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail. 2011;13(6):611-8. doi:10.1093/eurjhf/hfr014.

11. Tschöpe C, Müller I, Xia Y, et al. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circ Heart Fail. 2017;10(9):e003870. doi:10.1161/CIRCHEARTFAILURE.117.003870.

12. Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15(2):117-29. doi:10.1038/nri3800.

13. Cabrerizo M, Díaz-Cerio M, Muñoz-Almagro C, et al. Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4-year period in Spain. J Med Virol. 2017;89(3):435-42. doi:10.1002/jmv.24658.

14. Chen J, Tang Y, Zhu M, et al. Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis. Clin Rheumatol. 2016;35(10):2437-48. doi:10.1007/s10067-016-3373-z.

15. Nussinovitch U, Shoenfeld Y. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol. 2013;44(1):98-108. doi:10.1007/s12016-010-8229-8.

16. Кобалава Ж. Д., Лазарев П. В., Гончаров А. С. Современный взгляд на проблемы патогенеза, диагностики и лечения алкогольной кардиомиопатии. Российский кардиологический журнал. 2019;24(11):164-72. doi:10.15829/1560-40712019-11-164-172.

17. Manthey J, Imtiaz S, Neufeld M, et al. Quantifying the global contribution of alcohol consumption to cardiomyopathy. Popul Health Metr. 2017;15(1):20. doi:10.1186/s12963017-0137-1.

18. Piano MR, Phillips SA. Alcoholic cardiomyopathy: pathophysiologic insights. Cardiovasc Toxicol. 2014;14(4):291-308. doi:10.1007/s12012-014-9252-4.

19. Hantson P. Mechanisms of toxic cardiomyopathy. Clin Toxicol (Phila). 2019;57(1):1-9. doi:10.1080/15563650.2018.1497172.

20. Havakuk O, Rezkalla SH, Kloner RA. The Cardiovascular Effects of Cocaine. J Am Coll Cardiol. 2017;70(1):101-13. doi:10.1016/j.jacc.2017.05.014.

21. Varga ZV, Ferdinandy P, Liaudet L, et al. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(9):H1453-67. doi:10.1152/ajpheart.00554.2015.

22. Barnes KAS, Fasanmi EO, Iwuorie OP, et al. Cocaine-Induced Cardiomyopathy. US Pharm. 2015;40(2):HS11-HS15.

23. Kevil CG, Goeders NE, Woolard MD, et al. Methamphetamine Use and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019;39(9):1739-46. doi:10.1161/ATVBAHA.119.312461.

24. Sevak RJ, Vansickel AR, Stoops WW, et al. Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole. J Clin Psychopharmacol. 2011;31:470-80.

25. Zhao SX, Kwong C, Swaminathan A, et al. Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy. JACC Heart Fail. 2018;6:209-18.

26. Perry JC, Schuetz TM, Memon MD, et al. Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus. 2020;12(7):e9333. doi:10.7759/cureus.9333.

27. Torrisi M, Pennisi G, Russo I, et al. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina (Kaunas). 2020;56(11):587. doi:10.3390/medicina56110587.

28. D’Andrea A, Radmilovic J, Caselli S, et al. Left atrial myocardial dysfunction after chronic abuse of anabolic androgenic steroids: a speckle tracking echocardiography analysis. Int J Cardiovasc Imaging. 2018;34(10):1561. doi:10.1007/s10554-018-1409-y.

29. Angelini G, Pollice P, Lepera ME, et al. Irreversible Dilated Cardiomyopathy After Abuse of Anabolic Androgenic Steroids: A Case Report and Literature Review Biomed J Sci & Tech Res. 2019;21(4). doi:10.26717/BJSTR.2019.21.003648.

30. Zamorano JL, Lancellotti P, Munoz DR, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-801. doi:10.1093/eurheartj/ehw211. Erratum in: Eur Heart J. 2018;39(10):839. doi:10.1093/eurheartj/ehw562.

31. Murabito A, Hirsch E, Ghigo A. Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer? Frontiers in Cardiovascular Medicine. 2020;7:1-12. doi:10.3389/fcvm.2020.00035.

32. Гендлин Г. Е., Емелина Е. И., Никитин И. Г., Васюк Ю. А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017;(3):145-54. doi:10.15829/1560-4071-2017-3-145-154.

33. Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 2020;29:101394. doi:10.1016/j.redox.2019.101394.

34. Wang J, Zhang J, Xiao M, et al. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cellular and Molecular Life Sciences. 2021;78:3105-25. doi:10.1007/s00018-020-03729-y.

35. Mohan N, Jiang J, Dokmanovic M, et al. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antibody Therapeutics. 2018:1:1:13-7. doi:10.1093/abt/tby003.

36. Wu Q, Bai B, Tian C, et al. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. Cardiovasc Drugs Ther. 2022;36(3):511-24. doi:10.1007/s10557-021-07181-3.

37. Гумерова К. С., Сахаутдинова Г. М., Полякова И. М. Кардиоваскулярная токсичность, индуцированная применением противоопухолевых препаратов, и современные методы лечения опухолевых новообразований. Креативная хирургия и онкология. 2019;9(4):285-92. doi:10.24060/2076-3093-20199-4-285-292.

38. Wu P, Oren O, Gertz MA, Yang EH. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. Curr Oncol Rep. 2020;22(7):66. doi:10.1007/s11912-020-00931-w.

39. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88. doi:10.1016/S0140-6736(18)32203-7.

40. Самородская И. В., Старинская М. А., Семёнов В. Ю., Какорина Е. П. Нозологическая и возрастная структура смертности от болезней системы кровообращения в 2006 и 2014 годах. Российский кардиологический журнал. 2016;(6):7-14. doi:10.15829/1560-4071-2016-6-7-14.

41. Halliday BP, Gulati A, Ali A, et al. Sexand age-based differences in the natural history and outcome of dilated cardiomyopathy. Eur J Heart Fail. 2018;20(10):1392-400. doi:10.1002/ejhf.1216.

42. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др. Первые результаты национального эпидемиологического исследования — Эпидемиологическое Обследование больныХ ХСН в реальной прАктике (по Обращаемости) — ЭПОХА-О-ХСН. Сердечная недостаточность. 2003;4(3):116-9.

43. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016;37:1850-8. doi:10.1093/eurheartj/ehv727.

44. Емелина Е. И., Ибрагимова А. А., Ганиева И. И. и др. Ремоделирование сердца у больных с тяжелой систолической дисфункцией, возникшей на фоне противоопухолевой терапии. Кардиология. 2020;60(3):51-8. doi:10.18087/cardio.2020.3.n952.

45. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине. Под ред. П. Либби и др.; пер. с англ., под общ. ред. Р. Г. Оганова. В 4 т. Том 4: главы 61-89. М.: Логосфера, 2015. 808 с.: ил. ISBN: 978-5-98657-048-8.

46. Галявич А. С., Терещенко С. Н., Ускач Т. М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. doi:10.15829/1560-4071-2024-6162.

47. Шляхто Е. В. Кардиология: национальное руководство. Под ред. Е. В. Шляхто. Москва: ГЭОТАР-Медиа, 2015. 560 с.

48. Dziewięcka E, Gliniak M, Winiarczyk M, et al. The burden of atrial fibrillation and its prognostic value in patients with dilated cardiomyopathy. Kardiol Pol. 2020;78(1):37-44. doi:10.33963/KP.15046.

49. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017; 390(10092):400-14. doi:10.1016/S0140-6736(16)31713-5.

50. Руководство по эхокардиографической диагностике. Под ред. Франка А. Флакскампфа; пер. с нем.; под общ. ред. В. А. Сандрикова. 2-е изд. Москва: МЕДпресс-информ, 2019. 872 с: ил. + 1 CD. ISBN: 9785-00030-662-8.

51. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003.

52. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021;42(48):4901. doi:10.1093/eurheartj/ehab670.

53. Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies. Circulation. 2016;134:e579-e646. doi:10.1161/CIR.0000000000000455.

54. Bozkurt B, Hershberger RE, Butler J, et al. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). J Am Coll Cardiol. 2021;77(16):2053-150. doi:10.1016/j.jacc.2020.11.012.

55. George A, Figueredo VM. Alcoholic Cardiomyopathy: A Review. J Card Fail. 2011;17(10): 844-9. doi:10.1016/j.cardfail.2011.05.008.

56. Арутюнов Г. П., Палеев Ф. Н., Моисеева О. М. и др. Миокардиты у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(11):4790. doi:10.15829/1560-4071-2021-4790.

57. Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389-98. doi:10.1093/cvr/cvx012.

58. Peterson LR, Gropler RJ. Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy. Circ Res. 2020;126(11):1628-45. doi:10.1161/CIRCRESAHA.120.315899.

59. Veronese G, Ammirati E, Cipriani M, et al. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol J Cardiol. 2018;19(4):279-286.

60. Ammirati E, Veronese G, Cipriani M, et al. Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment. Curr Cardiol Rep. 2018;20(11):114.

61. Хащевская Д. А., Митрофанова Л. Б., Белякова Е. А. и др. Аутоиммунитет и прогноз больных с морфологически документированным миокардитом. Кардиология. 2016;6:50-7.

62. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-89. doi:10.1016/j.jacc.2017.03.011.

63. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012.

64. Porter TR, Shillcutt SK, Adams MS, et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(1):40-56. doi:10.1016/j.echo.2014.09.009.

65. EchoNoRMAL (Echocardiographic Normal Ranges Meta-Analysis of the Left Heart) Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8:656-65. doi:10.1016/j.jcmg.2015.02.014.

66. Alherbish A, Becher H, Alemayehu W, et al. Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. 2018;35(11):1746-54. doi:10.1111/echo.14152.

67. Hoffmann R, Barletta G, von Bardeleben S, et al. Analysis of left ventricular volumes and function — a multicenter comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast enhanced 2D and 3D echocardiography. J Am Soc Echocardiogr. 2014;27:292-301. doi:10.1016/j.echo.2013.12.005.

68. Thavendiranathan P, Poulin F, Lim KD, et al. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review. J Am Coll Cardiol. 2014;63:2751-68. doi:10.1016/j.jacc.2014.01.073.

69. Mignot A, Donal E, Zaroui A, et al. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J Am Soc Echocardiogr. 2010;23:1019-24. doi:10.1016/j.echo.2010.07.019.

70. Yingchoncharoen T, Agarwal S, Popovic ZB, et al. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013;26:185-91. doi:10.1016/j.echo.2012.10.008.

71. Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314. doi:10.1016/j.echo.2016.01.011.

72. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. Am Soc Echocardiogr. 2010;23:685-713.

73. Saric M, Armour AC, Arnaout MS, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016;29(1):1-42. doi:10.1016/j.echo.2015.09.011.

74. Khemka A, Sawada SG. Dobutamine echocardiography for assessment of viability in the current era. Curr Opin Cardiol. 2019;34(5):484-9. doi:10.1097/HCO.0000000000000658.

75. Finocchiaro G, Merlo M, Sheikh N, et al. The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. Eur J Heart Fail. 2020;22(7):1097-107. doi:10.1002/ejhf.1815.

76. Макаров Л. М., Комолятова В. Н., Куприянова О. О. и др. Национальные Российские рекомендации по применению методики холтеровского мониторирования в клинической практике. Российский кардиологический журнал. 2014;(2):6-71. doi:10.15829/1560-4071-2014-2-6-71.

77. Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12:276-83.

78. Choi Y, Kim SM, Lee SC, et al. Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria. J Cardiovasc Magn Reson. 2016;18:24.

79. Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. European heart journal cardiovascular Imaging. 2015;16:14-22.

80. Kalb B, Indik JH, Ott P, et al. MRI of patients with implanted cardiac devices. J Magn Reson Imaging. 2018;47(3):595-603. doi:10.1002/jmri.25824.

81. Игнатьева Е. С., Рыжкова Д. В., Митрофанова Л. Б., Моисеева О. М. Возможности магнитно-резонансной томографии в диагностике различных клинико-морфологических форм миокардита. Российский кардиологический журнал. 2017;(2):30-8.

82. Jolicoeur EM, Dunning A, Castelvecchio S, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. J Am Coll Cardiol. 2015;66:2092-100. doi:10.1016/j.jacc.2015.08.882.

83. Paech DC, Weston AR. A systematic review of the clinical effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of suspected coronary artery disease. BMC Cardiovasc Disord. 2011;11:32. doi:10.1186/1471-2261-11-32.

84. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012;367:299-308. doi:10.1056/NEJMoa1201161.

85. Beanlands RSB, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-12. doi:10.1016/j.jacc.2007.09.006.

86. Holzmann M, Nicko A, Kuhl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation. 2008;118:1722-8.

87. Jessup M, Drazner MH, Book W, et al. 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/ AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. J Am Coll Cardiol. 2017 20;69(24):2977-3001. doi:10.1016/j.jacc.2017.03.001. Erratum in: J Am Coll Cardiol. 2018;71(16):1840.

88. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-9. doi:10.1093/eurjhf/hfn013.

89. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the HFA of the ESC, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544-58.

90. Колоскова Н. Н., Шаталов К. В., Бокерия Л. А. Определение пикового потребления кислорода: физиологические основы и области применения. Креативная кардиология. 2014;1:48-56.

91. Van den Broek SA, Veldhuisen DJ, de Graeff PA. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1992;70:359-63.

92. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004.

93. Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nat Rev Cardiol. 2020;17(5):286-97. doi:10.1038/s41569-019-0284-0.

94. Fatkin D, Huttner IG, Kovacic JC, et al. Precision Medicine in the Management of Dilated Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(23):2921-38. doi:10.1016/j.jacc.2019.10.011.

95. Martinez HR, Beasley GS, Miller N, et al. Clinical Insights Into Heritable Cardiomyopathies. Front Genet. 2021;12:663450. doi:10.3389/fgene.2021.663450.

96. Chen SN, Mestroni L, Taylor MRG. Genetics of dilated cardiomyopathy. Curr Opin Cardiol. 2021;36(3):288-94. doi:10.1097/HCO.0000000000000845.

97. Jordan E, Hershberger RE. Considering complexity in the genetic evaluation of dilated cardiomyopathy. Heart. 2021;107(2):106-12. doi:10.1136/heartjnl-2020-316658.

98. Wilsbacher LD. Clinical Implications of the Genetic Architecture of Dilated Cardiomyopathy. Curr Cardiol Rep. 2020;22(12):170. doi:10.1007/s11886-020-01423-w.

99. Marrow BA, Cook SA, Prasad SK, McCann GP. Emerging Techniques for Risk Stratification in Nonischemic Dilated Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(10):1196-207. doi:10.1016/j.jacc.2019.12.058.

100. Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. Circulation. 2020;141(5):387-98. doi:10.1161/CIRCULATIONAHA.119.037661.

101. Peters S, Johnson R, Birch S, et al. Familial Dilated Cardiomyopathy. Heart Lung Circ. 2020;29(4):566-74. doi:10.1016/j.hlc.2019.11.018.

102. Kelly MA, Caleshu C, Morales A, et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20(3):351-9. doi:10.1038/gim.2017.218.

103. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30.

104. Morales A, Kinnamon DD, Jordan E, et al.; Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. Circ Genom Precis Med. 2020;13(2):e002480. doi:10.1161/CIRCGEN.119.002480.

105. Müllertz KM, Christiansen MK, Broendberg AK, et al. Outcome of clinical management in relatives of sudden cardiac death victims. Int J Cardiol. 2018;262:45-50. doi:10.1016/j.ijcard.2018.03.022.

106. Stiles MK, Wilde AAM, Abrams DJ, et al. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. J Arrhythm. 2021;37(3):481-534. doi:10.1002/joa3.12449.

107. Gigli M, Merlo M, Graw SL, et al. Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol. 2019;74(11):1480-90. doi:10.1016/j.jacc.2019.06.072.

108. Seferović PM, Tsutsui H, Mcnamara DM, et al. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. J Card Fail. 2021;27(7):727-43. doi:10.1016/j.cardfail.2021.04.010.

109. Katzmann JL, Schlattmann P, Rigopoulos AG, et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Fail Rev. 2020;25(2):277-94. doi:10.1007/s10741-019-09835-9.

110. Leone O, Veinot JP, Angelini A, et al. Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21:245-74. doi:10.1016/j.carpath.2011.10.001.

111. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the EuropeanSociety of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21:827.

112. Barasa A, Rosengren A, Sandström TZ, et al. Heart Failure in Late Pregnancy and Postpartum: Incidence and Long-Term Mortality in Sweden From 1997 to 2010. J Card Fail. 2017;23:370.

113. Blagova OV, Krasnykh AV, Kogan EA. Diseases of the myocardium and pericardium. Moscow: Geotar-Media, 2019. 884 p. (In Russ.) Благова О. В., Недоступ А. В., Коган Е. А. Болезни миокарда и перикарда. М.: Гэотар-Медиа, 2019. 884 с.

114. Ware JS, Li J, Mazaika E, et al. Shared genetic pre-disposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233-41. doi:10.1056/NEJMoa1505517.

115. Goli R, Li J, Brandimarto J, et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation 2021;143:1852-62. doi:10.1161/CIRCULATIONAHA.120.052395.

116. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol. 2015;110(6):60. doi:10.1007/s00395-015-0517-2.

117. Sheppard R, Hsich E, Damp J, et al. GNB3 C825T Polymorphism and Myocardial Recovery in PeripartumCardiomyopathy: Results of the Multicenter Investigations of PregnancyAssociated CardiomyopathyStudy. Circ Heart Fail. 2016;9:e002683.

118. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.

119. Диагностика и лечение сердечно-сосудистых заболеваний при беременности. Национальные рекомендации 2018. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/15604071-2018-3-91-134.

120. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096-105. doi:10.1002/ejhf.586.

121. Haghikia A, Röntgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Fail. 2015;2(4):139-49. doi:10.1002/ehf2.12059.

122. Blauwet LA, Delgado-Montero A, Ryo K, et al.; IPAC Investigators. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes. Circ Heart Fail. 2016;9(5):e002756. doi:10.1161/CIRCHEARTFAILURE.115.002756.

123. Моисеев В. С., Киякбаев Г. К., Лазарев П. В. Кардиомиопатии и миокардиты М.: Гэотар-Медиа, 2020. 512 c.

124. Stătescu C, Clement A, Șerban IL, Sascău R. Consensus and Controversy in the Debate over the Biphasic Impact of Alcohol Consumption on the Cardiovascular System. Nutrients. 2021;13(4):1076. doi:10.3390/nu13041076.

125. Fernández-Solà J. The Effects of Ethanol on the Heart: Alcoholic Cardiomyopathy. Nutrients. 2020;12(2):572. doi:10.3390/nu12020572.

126. Rehm J, Hasan OSM, Imtiaz S, Neufeld M. Quantifying the contribution of alcohol to cardiomyopathy: A systematic review. Alcohol. 2017;61:9-15. doi:10.1016/j.alcohol.2017.01.011.

127. Mirijello A, Tarli C, Vassallo GA, et al. Alcoholic cardiomyopathy: What is known and what is not known. Eur J Intern Med. 2017;43:1-5. doi:10.1016/j.ejim.2017.06.014.

128. Моисеев В. С., Кобалава Ж. Д., Маев И. В. и др. Основы внутренней медицины. Руководство в 2 томах, 2-е издание. Москва: ООО "Медицинское информационное агентство"; 2020. 688 с.

129. Fang W, Luo R, Tang Y, et al. The Prognostic Factors of Alcoholic Cardiomyopathy: A single-center cohort study. Medicine (Baltimore). 2018;97(31):e11744. doi:10.1097/MD.0000000000011744.

130. Tasnim S, Tang C, Musini VM, Wright JM. Effect of alcohol on blood pressure. Cochrane Database Syst Rev. 2020;7(7):CD012787. doi:10.1002/14651858.CD012787.

131. Steinkohl F, Barbieri F, Senoner T, et al. Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. Eur Radiol. 2021;31(1):494-503. doi:10.1007/s00330-020-07037-8.

132. van de Luitgaarden IAT, Schrieks IC, Kieneker LM, et al. Urinary Ethyl Glucuronide as Measure of Alcohol Consumption and Risk of Cardiovascular Disease: A PopulationBased Cohort Study. J Am Heart Assoc. 2020;9(7):e014324. doi:10.1161/JAHA.119.014324.

133. Sulaiman S, Yousef N, Benjamin MM, et al. Burden of arrhythmia and electrophysiologic procedures in alcoholic cardiomyopathy hospitalizations. Int J Cardiol. 2020;304:61-8. doi:10.1016/j.ijcard.2020.01.068.

134. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155722 individuals from 21 high-income, middle-income, and lowincome countries (PURE): A prospective cohort study. Lancet. 2020;395(10226):795808. doi:10.1016/S0140-6736(19)32008-2. Erratum in: Lancet. 2020;395(10226):784. doi:10.1016/S0140-6736(19)32282-2.

135. Гуревич М. А., Кузьменко Н. А. Алкогольное поражение сердца. Русский медицинский журнал. 2019;19:1281-4.

136. Curigliano G, Lenihan D, Fradeley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31:171-90.

137. Leger KJ, Baker KS, Cushing-Haugen KL, et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018;124(7):1507-15. doi:10.1002/cncr.31227.

138. Васюк Ю. А., Гендлин Г. Е., Емелина Е. И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703. doi:10.15829/1560-4071-2021-4703.

139. Чазова И. Е., Агеев Ф. Т., Аксенова А. В. и др. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022;(1):6-79. doi:10.38109/2225-16852022-1-6-79.

140. Taylor C, Correa C, Duane FK, et al.; Early Breast Cancer Trialists’ Collaborative Group. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017 20;35(15):1641-9. doi:10.1200/JCO.2016.72.0722.

141. Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-361. doi:10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023;44(18):1621. doi:10.1093/eurheartj/ehad196.

142. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, doubleblind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-80. doi:10.1093/eurheartj/ehw022.

143. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870-7. doi:10.1200/JCO.2016.68.7830.

144. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20): 2281-90. doi:10.1016/j.jacc.2018.02.049.

145. Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859-68. doi:10.1016/j.jacc.2019.03.495.

146. Soler R, Méndez C, Rodríguez E, et al. Phenotypes of hypertrophic cardiomyopathy. An illustrative review of MRI findings. Insights Imaging. 2018;9(6):1007-20. doi:10.1007/s13244018-0656-8.

147. Musumeci B, Tini G, Russo D, et al. Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. J Clin Med. 2021;10(8):1547. doi:10.3390/jcm10081547.

148. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195.

149. Шляхто Е. В., Звартау Н. Э., Виллевальде С. В. и др. Реализованные модели и элементы организации медицинской помощи пациентам с сердечной недостаточностью в регионах Российской Федерации: перспективы трансформации в региональные системы управления сердечно-сосудистыми рисками. Российский кардиологический журнал. 2020;25(4):3792. doi:10.15829/1560-4071-2020-4-3792.

150. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11-21. doi:10.1056/NEJMoa1009492.

151. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

152. Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

153. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-8. doi:10.1016/S0140-6736(20)30748-0.

154. Мареев Ю. В., Мареев В. Ю. Возможности современной терапии в улучшении прогноза при хронической сердечной недостаточности: фокус на ангиотензиновых рецепторов и неприлизина ингибиторах и ингибиторах натрий глюкозного транспортера. Кардиология. 2021;61(6):4-10. doi:10.18087/cardio.2021.6.n1678.

155. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi:10.1056/NEJMoa1409077.

156. Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction, European Heart Journal. 2016;37(43):3293-302. doi:10.1093/eurheartj/ehw241.

157. Chandra A, Lewis EF, Claggett BL, et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiology. 2018;3(6):498-505. doi:10.1001/jamacardio.2018.0398.

158. Velazquez EJ, Morrow DA, DeVore AD, et al. for the PIONEER-HF Investigators Angiotensin– Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380:539-48. doi:10.1056/NEJMoa1812851.

159. Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352-61. doi:10.1161/CIRCULATIONAHA.119.044586.

160. Solomon SD, McMurray JJV, Anand IS, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-20. doi:10.1056/NEJMoa1908655.

161. Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Engl J Med. 2021;385(16):1451-61. doi:10.1056/NEJMoa2107038.

162. Packer M, Butler J, Zannad F, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved. Circulation. 2021;144(16):1284-94. doi:10.1161/CIRCULATIONAHA.121.056824.

163. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98. doi:10.1056/NEJMoa2206286.

164. Maggioni AP, Anand I, O Gottlieb S, et al. Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-21. doi:10.1016/s0735-1097(02)02304-5.

165. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM–Alternative trial. Lancet. 2003;362(9386):772-6. doi:10.1016/s0140-6736(03)14284-5.

166. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, doubleblind trial. HEAAL Investigators. Lancet. 2009;374(9704):1840-8. doi:10.1016/S01406736(09)61913-9.

167. Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11-22. doi:10.1007/s00392-012-0467-8.

168. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838. doi:10.1002/14651858.CD003838.

169. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551-9. doi:10.1093/eurjhf/hft010.

170. Malik A, Masson R, Singh S, et al. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology. 2019;74(5):617-27. doi:10.1016/j.jacc.2019.05.064.

171. Mages C, Gampp H, Syren P, et al. Electrical Ventricular Remodeling in Dilated Cardiomyopathy. Cells. 2021;10(10):2767. doi:10.3390/cells10102767.

172. Friedman DJ, Al-Khatib SM, Zeitler EP, et al. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. Am Heart J. 2017;191:21-9. doi:10.1016/j.ahj.2017.06.002.

173. Packer M. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure. JACC Heart Fail. 2019;7(10):902-6. doi:10.1016/j.jchf.2019.05.013.

174. Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757-63. doi:10.1093/eurheartj/ehz553.

175. Packer M. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator. Circ Arrhythm Electrophysiol. 2019;12(6):e007430. doi:10.1161/CIRCEP.119.007430.

176. Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A metaanalysis of 34 randomized controlled trials. Heart Rhythm. 2021: S1547-5271(21)00239-3. doi:10.1016/j.hrthm.2021.03.028.

177. Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF Eur Heart J. 2021;42(36):3727-38. doi:10.1093/eurheartj/ehab560.

178. Shimizu W, Kubota Y, Hoshika Y, et al. EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020;19(1):148. doi:10.1186/s12933-020-01127-z.

179. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348(9019):7-12. doi:10.1016/s0140-6736(96)02149-6.

180. Connolly SJ, Camm AJ, Halperin JL, et al. PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76. doi:10.1056/NEJMoa1109867.

181. Hasin T, Davarashvili I, Michowitz Y, et al. Association of Guideline-Based Medical Therapy with Malignant Arrhythmias and Mortality among Heart Failure Patients Implanted with Cardioverter Defibrillator (ICD) or Cardiac Resynchronization-Defibrillator Device (CRTD). J Clin Med. 2021;10(8):1753. doi:10.3390/jcm10081753.

182. Adelstein EC, Althouse AD, Davis L, et al. Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy-defibrillators. J Cardiovasc Electrophysiol. 2019;30(3):348-56. doi:10.1111/jce.13828.

183. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990-97. doi:10.1093/eurheartj/ehv186.

184. Januzzi JLJr, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. PROVE-HF Investigators. JAMA. 2019;322(11):1085-95. doi:10.1001/jama.2019.12821.

185. Køber L, Thune JJ, Nielsen JC, et al.; DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi:10.1056/NEJMoa1608029.

186. Elming MB, Nielsen JC, Haarbo J, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation. 2017;136(19):1772-80. doi:10.1161/CIRCULATIONAHA.117.028829.

187. Bristow MR, Saxon LA, Feldman AM, et al. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. JACC Heart Fail. 2016;4(7):521-35. doi:10.1016/j.jchf.2016.02.019. Erratum in: JACC Heart Fail. 2017;5(1):75-9. doi:10.1016/j.jchf.2016.12.001.

188. Prabhu S, Costello BT, Taylor AJ, et al. Regression of Diffuse Ventricular Fibrosis Following Restoration of Sinus Rhythm With Catheter Ablation in Patients With Atrial Fibrillation and Systolic Dysfunction: A Substudy of the CAMERA MRI Trial. JACC Clin Electrophysiol. 2018;4(8):999-1007. doi:10.1016/j.jacep.2018.04.013.

189. Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю., Голицын С. П. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.

190. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. doi:10.1093/eurheartj/ehae176. Erratum in: Eur Heart J. 2025;46(41):4349. doi:10.1093/eurheartj/ehaf306.

191. Hess PL, Sheng S, Matsouaka R, et al. Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines — Heart Failure Program). Am J Cardiol. 2020;125(6):894-900. doi:10.1016/j.amjcard.2019.12.025.

192. Elayi CS, Shohoudi A, Moodie E, et al. AF-CHF Investigators. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. Int J Cardiol. 2020;313:48-54. doi:10.1016/j.ijcard.2020.04.047.

193. Davila LA, Weber K, Bavendiek U, et al. Digoxin–mortality: randomized vs. observational comparison in the DIG trial. European Heart Journal. 2019;40:3336-41. doi:10.1093/eurheartj/ehz395.

194. Marrouche NF, Brachmann J, Andresen D, et al. CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27. doi:10.1056/NEJMoa1707855.

195. Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017;70(16):1949-61. doi:10.1016/j.jacc.2017.08.041.

196. Kuck KH, Merkely B, Zahn R, et al. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial. Circ Arrhythm Electrophysiol. 2019;12(12):e007731. doi:10.1161/CIRCEP.119.007731.

197. Ревишвили А. Ш., Глезер М. Г., Артюхина Е. А. и др. Брадиаритмии и нарушения проводимости. Клинические рекомендации 2025. Российский кардиологический журнал. 2025;30(11):6669. doi:10.15829/1560-40712025-6669. EDN: PDTCGN.

198. Попов С. В., Давтян К. В., Шубик Ю. В. и др. Наджелудочковые тахикардии. Клинические рекомендации 2025. Российский кардиологический журнал. 2025;30(7):6448. doi:10.15829/15604071-2025-6448. EDN: ZLGSCN.

199. Hasselberg NE, Edvardsen T, Petri H, et al. Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects. Europace. 2014;16(4):563-71. doi:10.1093/europace/eut291.

200. Anselme F, Moubarak G, Savouré A, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10(10):1492-8. doi:10.1016/j.hrthm.2013.06.020.

201. Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019;140(4):293-302. doi:10.1161/CIRCULATIONAHA.118.039410.

202. Feingold B, Mahle WT, Auerbach S, et al. American Heart Association Pediatric Heart Failure Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Stroke Council. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017;136(13):e200-e231. doi:10.1161/CIR.0000000000000526.

203. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150(1):54-8. doi:10.1016/j.ijcard.2010.02.029.

204. Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II. Pacing Clin Electrophysiol. 2012;35(10):1262-9. doi:10.1111/j.1540-8159.2012.03351.x.

205. Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in KearnsSayre syndrome and mitochondrial cytopathy. Int J Cardiol. 2015;181:303-10. doi:10.1016/j.ijcard.2014.12.038.

206. Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-83. doi:10.1016/j.jchf.2018.04.010. Erratum in: JACC Heart Fail. 2023;11(1):132. doi:10.1016/j.jchf.2022.11.003.

207. Вандер М. А., Лясникова Е. А., Белякова Л. А. и др. Твердые конечные точки у пациентов с хронической сердечной недостаточностью с низкой фракцией выброса левого желудочка на фоне модуляции сердечной сократимости в течение двух лет наблюдения. Российский кардиологический журнал. 2020;25(7):3853. doi:10.15829/1560-4071-2020-3853.

208. Вандер М. А., Лясникова Е. А., Белякова Л. А. и др. Динамика маркеров выраженности хронической сердечной недостаточности и обратное ремоделирование миокарда на фоне модуляции сердечной сократимости. Российский кардиологический журнал. 2021;26(1):4035. doi:10.15829/1560-4071-2021-4035.

209. Muser D, Liang JJ, Witschey WR, et al. Ventricular arrhythmias associated with left ventricular noncompaction: Electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2017;14(2):166-75. doi:10.1016/j.hrthm.2016.11.014.

210. Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10:172-5. doi:10.1016/j.hrthm.2012.10.011.

211. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22:663-8. doi:10.1111/j.1540-8167.2010.01986.x.

212. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549. Erratum in: Circulation.2018;138(13):e419-e420. doi:10.1161/CIR.0000000000000614.

213. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm. 2014;11(3):360-6. doi:10.1016/j.hrthm.2013.11.028.

214. Sulaica EM, Macaulay TE, Helbing RR, et al. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(2):207-16. doi:10.1007/s10741-019-09818-w.

215. Ueyama H, Takagi H, Briasoulis A, et al. Meta-Analysis of Antithrombotic Strategies in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm. Am J Cardiol. 2020;127:92-8. doi:10.1016/j.amjcard.2020.04.007.

216. Shantsila E, Kozieł M, Lip GY. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2021;5(5):CD003336. doi:10.1002/14651858.CD003336.

217. Konstantinides SV. Рекомендации ESC по диагностике и лечению острой легочной эмболии, разработанные в сотрудничестве с Европейским респираторным обществом (ERS), 2019. Российский кардиологический журнал. 2020;25(8):3848. doi:10.15829/1560-4071-2020-3848.

218. Mizia-Stec K, Caforio ALP, Charron P, et al. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Fail. 2020;7(6):3601-9. doi:10.1002/ehf2.12854.

219. Daher J, Da Costa A, Hilaire C, et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig. 2020;40(4):343-53. doi:10.1007/s40261-020-00898-3.

220. Guddeti RR, Anwar M, Walters RW, et al. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020;133(12):1488-91. doi:10.1016/j.amjmed.2020.05.025.

221. Trongtorsak A, Thangjui S, Kewcharoen J, et al. Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis. Acta Cardiol. 2021;76(9):933-42. doi:10.1080/00015385.2020.1858538.

222. Burmeister C, Beran A, Mhanna M, et al. Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis. Am J Ther. 2021;28(4):e411-e419. doi:10.1097/MJT.0000000000001351.

223. Chen R, Zhou J, Liu C, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus: a systematic review and meta-analysis. Pol Arch Intern Med. 2021;131(5):429-38. doi:10.20452/pamw.15923.

224. Hu ZC, Wu LM, Liu SY, et al. Clinical characteristics of cardiomyopathies complicated with ventricular thrombosis. Zhonghua Yi Xue Za Zhi. 2019;99(45):3587-91. Chinese. doi:10.3760/cma.j.issn.0376-2491.2019.45.011.

225. Michael F, Natt N, Shurrab M. Direct Oral Anticoagulants vs Vitamin K Antagonists in Left Ventricular Thrombi: A Systematic Review and Meta-analysis. CJC Open. 2021;3(9):1169-81. doi:10.1016/j.cjco.2021.04.007.

226. Condello F, Maurina M, Chiarito M, et al. Direct oral anticoagulants versus Vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis. Minerva Cardiol Angiol. 2022;70(6):666-76. doi:10.23736/S2724-5683.21.05893-2.

227. Labbene I, Arrigo M, Tavares M, et al. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2017;36(1):39-42. doi:10.1016/j.accpm.2016.02.009.

228. Davis MB, Arany Z, McNamara DM, el al. JACC State-of-the-Art Review. Peripartum Cardiomyopathy. Am Coll Cardiol 2020;75(2):207-21. doi:10.1016/j.jacc.2019.11.014.

229. Hilfiker-Kleiner D. Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: A ulticenter randomized study. Eur Heart J. 2017;38(35):2671-9. doi:10.1093/eurheartj/ehx355.

230. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017;19(9):1131-41. doi:10.1002/ejhf.780.

231. Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020;41(39):3787-97. doi:10.1093/eurheartj/ehaa455.

232. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol. 2014;63(25 Pt A):2831-9. doi:10.1016/j.jacc.2014.04.014.

233. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum сardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012;18:21-7. doi:10.1016/j.cardfail.2011.09.004.

234. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-35. doi:10.1002/ejhf.1236.

235. Ситникова М. Ю., Лясникова Е. А., Юрченко А. В. и др. Результаты 3 лет работы Российского госпитального регистра хронической сердечной недостаточности (RUssian hoSpital Heart Failure Registry — RUS-HFR): взаимосвязь менеджмента и исходов у больных хронической сердечной недостаточностью. Кардиология. 2018;58(10S):9-19. doi:10.18087/cardio.2483.

236. Kida K, Doi S, Suzuki N. Palliative Care in Patients with Advanced Heart Failure. Heart Fail Clin. 2020;16(2):243-54. doi:10.1016/j.hfc.2019.12.006.

237. Mullens W, Damman K, Harjola VP, еt аl. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(7):949-50. doi:10.1002/ejhf.1369.

238. Alqahtani F, Koulouridis I, Susantitaphong P, et al. A meta-analysis of continuous vs intermittent infusion of loop diuretics in hospitalized patients. J Crit Care. 2014;29(1):10-7. doi:10.1016/j.jcrc.2013.03.015.

239. Rossignol P, Coats AJ, Chioncel O, еt аl. Renal function, electrolytes, and congestion monitoring in heart failure. Eur Heart J Suppl. 2019;21(Suppl M): M25-M31. doi:10.1093/eurheartj/suz220. Erratum in: Eur Heart J Suppl. 2019;21(Suppl M): M72. doi:10.1093/eurheartj/suab013.

240. Rossignol P, Fay R, Girerd N, et al. Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post-discharge. ESC Heart Fail. 2020;7(3):1257-63. doi:10.1002/ehf2.12642.

241. Gong B, Li Z, Yat Wong PC. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415-25. doi:10.1053/j.jvca.2015.03.023.

242. Pashkovetsky E, Gupta CA, Aronow WS. Use of levosimendan in acute and advanced heart failure: short review on available real-world data. Ther Clin Risk Manag. 2019;15:765-72. doi:10.2147/TCRM.S188761.

243. Heringlake M, Alvarez J, Bettex D, et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev Cardiovasc Ther. 2021;19(4):325-35. doi:10.1080/14779072.2021.1905520.

244. Fedotov PA, Simonenko MA, Sazonova YV, et al. Mortality Risk Factors in Patients who are in Heart Transplantation Waiting List. OBM Transplantation. 2019;3(3):1-18. doi:10.21926/ obm.transplant.1903077.

245. Fang JC, Ewald GA, Allen LA, et al.; Heart Failure Society of America Guidelines Committee. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21(6):519-34. doi:10.1016/j.cardfail.2015.04.013.

246. Kazory A, Costanzo MR. Extracorporeal Isolated Ultrafiltration for Management of Congestion in Heart Failure and Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018;25(5):434-42. doi:10.1053/j.ackd.2018.08.007.

247. Hupcey JE, Kitko L, Alonso W. Patients’ perceptions of illness severity in advanced heart failure. J Hosp Palliat Nurs. 2016;18(2):110-4. doi:10.1097/NJH.0000000000000229.

248. Lowey SE. Palliative Care in the Management of Patients with Advanced Heart Failure. Adv Exp Med Biol. 2018;1067:295-311. doi:10.1007/5584_2017_115.

249. Ahmedzai SH. Breathlessness in advanced disease. Medicine. 2020;48(1):23-8. doi:10.1016/j.mpmed.2019.10.004.

250. Fu MR, Li Y, Conway C, et al. The Effects of Exercise-Based Interventions on Fluid Overload Symptoms in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Biomedicines. 2022;10(5):1111. doi:10.3390/biomedicines10051111.

251. León Delgado M, Campos LR, Bastidas Goyes A, et al. Opioids for the management of dyspnea in patients with heart failure: a systematic review of the literature. Colombian Journal of Anesthesiology. 2019;47:49-56. doi:10.1097/cj9.0000000000000088.

252. Celano CM, Villegas AC, Albanese AM, et al. Depression and Anxiety in Heart Failure: A Review. Harv Rev Psychiatry. 2018;26(4):175-84. doi:10.1097/HRP.0000000000000162.

253. Balon R, Rafanelli C, Sonino N. Benzodiazepines: A Valuable Tool in the Management of Cardiovascular Conditions. Psychother Psychosom. 2018;87(6):327-30. doi:10.1159/000493015.

254. Lindgren M, Börjesson M. The importance of physical activity and cardiorespiratory fitness for patients with heart failure. Diabetes Res Clin Pract. 2021;176:108833.doi:10.1016/j.diabres.2021.108833.

255. Cho J, Choi Y, Sajgalik P, et al. Exercise as a Therapeutic Strategy for Sarcopenia in Heart Failure: Insights into Underlying Mechanisms. Cells. 2020;9(10):2284. doi:10.3390/cells9102284.

256. Morotomi N, Sakuma K, Sakai K. Exercise Therapy for Patients with Heart Failure: Focusing on the Pathophysiology of Skeletal Muscle. Muscle Cell and Tissue. 2021:1-16. doi:10.5772/intechopen.97291.

257. Pinto CL, Botelho PB, Carneiro JA, Mota JF. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly: Creatine and resistance training in the elderly. Journal of Cachexia, Sarcopenia and Muscle. 2016;7(4):413-21. doi:10.1002/jcsm.12094.

258. Hill A, Heyland DK, Ortiz Reyes LA, et al. Combination of enteral and parenteral nutrition in the acute phase of critical illness: An updated systematic review and meta-analysis. JPEN J Parenter Enteral Nutr. 2022;46(2):395-410. doi:10.1002/jpen.2125.

259. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17) e263-e421. doi:10.1016/j.jacc.2021.12.012.

260. Javaid MR, Squirrell S, Farooqi F. Improving rates of implantable cardioverter defibrillator deactivation in end-of-life care. BMJ Open Qual. 2018;7(2):e000254. doi:10.1136/bmjoq-2017-000254.

261. Kinch Westerdahl A, Frykman V. Physicians’ knowledge of implantable defibrillator treatment: are we good enough? Europace. 2017;19:1163-9. doi:10.1093/europace/euw228.

262. Ferrell BR, Twaddle ML, Melnick A, et al. National Consensus Project Clinical Practice Guidelines for Quality Palliative Care Guidelines, 4th Edition. J Palliat Med. 2018;21(12):1684-9. doi:10.1089/jpm.2018.0431.

263. Александрова С. А., Апханова Т. В., Аронов Д. М. и др. Митральная недостаточность. Клинические рекомендации 2024. Грудная и сердечно-сосудистая хирургия. 2025;67(4):474-523. doi:10.24022/0236-2791-2025-67-4-474-523.

264. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group, 2021 ESC/ EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, 2021: ehab395. doi:10.1093/eurheartj/ehab395.

265. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-e227. doi:10.1161/CIR.0000000000000923.

266. Godino C, Scotti A, Taramasso M, et al. Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018;269:33-9. doi:10.1016/j.ijcard.2018.06.041.

267. Stone GW, Lindenfeld J, Abraham WT, et al. COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-18. doi:10.1056/NEJMoa1806640.

268. Boudoulas KD, Vallakati A, Pitsis AA, et al. The Use of MitraClip in Secondary Mitral Regurgitation and Heart Failure. Cardiovasc Revasc Med. 2020;21(12):1606-12. doi:10.1016/j.carrev.2020.05.015.

269. Shingu Y, Ooka T, Katoh H, et al. Feasibility and limitations of mitral valve repair, with or without left ventricular reconstruction in non-ischemic dilated cardiomyopathy. J Cardiol. 2018;71(4):329-35. doi:10.1016/j.jjcc.2017.09.013.

270. Muntané-Carol G, Alperi A, Faroux L, et al. Transcatheter Tricuspid Valve Intervention: Coaptation Devices. Front Cardiovasc Med. 2020;7:139. doi:10.3389/fcvm.2020.00139.

271. Kervan U, Unal EU, Sert DE, et al. HeartWare Left Ventricular Assist Device Implantation Combined with Surgical Ventricular Reconstruction. Exp Clin Transplant. 2019;17(2):278-80. doi:10.6002/ect.2016.0056.

272. Kadakia S, Moore R, Ambur V, Toyoda Y. Current status of the implantable LVAD. Gen Thorac Cardiovasc Surg. 2016;64(9):501-8. doi:10.1007/s11748-016-0671-y.

273. Kilic A, Emani S, Sai-Sudhakar CB, et al. Donor selection in heart transplantation. J Thorac Dis. 2014;6(8):1097-104. doi:10.3978/j.issn.2072-1439.2014.03.23.

274. Bernhardt AM, Copeland H, Deswal A, et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support. J Card Fail. 2023;29(3):304-74. doi:10.1016/j.cardfail.2022.11.003.

275. Møller JE, Thiele H, Morrow D, et al. Mechanical circulatory support: when, how, and for whom. Eur Heart J. 2025;46(16):1480-92. doi:10.1093/eurheartj/ehae925.

276. Russo JJ, Aleksova N, Pitcher I, et al. Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock. J Am Coll Cardiol. 2019;73(6):654-62. doi:10.1016/j.jacc.2018.10.085.

277. Рыбка М. М., Хинчагов Д. Я., Мумладзе К. В. и др. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации. М.: НЦССХ им. А. Н. Бакулева РАМН; 2018. 74 с. ISBN: 978-5-7982-0385-7.

278. Заболотских И. Б., Баутин А. Е., Замятин М. Н. и др. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология. 2019;3:5-24.

279. Landoni G, Lomivorotov VV, Nigro Neto C, et al. MYRIAD Study Group. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery. N Engl J Med. 2019;380(13):1214-225. doi:10.1056/NEJMoa1816476.

280. Потиевская В. И., Баутин А. Е. Сопутствующие заболевания системы кровообращения. В кн.: Интенсивная терапия: национальное руководство: в 2 т. Под ред. И. Б. Заболотских, Д. Н. Проценко. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2020. Т. 1. 1152 с.: ил. (Серия "Национальные руководства") сс. 396-451.

281. Ezekowitz JA, Colin-Ramirez E, Ross H, et al.; SODIUM-HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-400. doi:10.1016/s0140-6736(22)00369-5.

282. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology, Eur J Prev Cardiol. 2021;28(5):460-95.

283. Bozkurt B, Fonarow GC, Goldberg LR, et al. ACC’s Heart Failure and Transplant Section and Leadership Council. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel. J Am Coll Cardiol. 2021;77(11):1454-69. doi:10.1016/j.jacc.2021.01.030.

284. Sommaruga M, Angelino E, Della Porta P, et al. Best practice in psychological activities in cardiovascular prevention and rehabilitation: Position Paper. Monaldi Arch Chest Dis. 2018;88(2):47-83. doi:10.4081/monaldi.2018.966.

285. Rao A, Zecchin R, Newton PJ, et al. The prevalence and impact of depression and anxiety in cardiac rehabilitation: A longitudinal cohort study. Eur. J. Prev. Cardiol. 2020;27(5):478-89. doi:10.1177/2047487319871716.

286. Lovell J, Pham T, Noaman SQ, et al. Self-management of heart failure in dementia and cognitive impairment: a systematic review. BMC Cardiovasc Disord. 2019;19(1):99. doi:10.1186/s12872-019-1077-4.

287. Ткачева О. Н., Рунихина Н. К., Остапенко В. С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30:2:236-42.

288. Hansen D, Dendale P, Coninx K, et al. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol. 2017;24(10):1017-31. doi:10.1177/2047487317702042.

289. Laoutaris ID, Piotrowicz E, Kallistratos MS, et al., ARISTOS-HF trial (Aerobic, Resistance, InSpiratory Training OutcomeS in Heart Failure) Investigators. Combined aerobic/resistance/inspiratory muscle training as the ‘optimum’ exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial. Eur J Prev Cardiol. 2020: zwaa091. doi:10.1093/eurjpc/zwaa091.

290. Cao Z, Wang T, Xia W, et al. A Pilot Metabolomic Study on Myocardial Injury Caused by Chronic Alcohol Consumption-Alcoholic Cardiomyopathy. Molecules. 2021;26(8):2177. doi:10.3390/molecules26082177.

291. Мацкеплишвили С. Т., Потиевская В. И., Поповкина О. Е. и др. Сердечнососудистые осложнения при лечении онкологических заболеваний (кардиоонкология): профилактика, диагностика, лечение — cогласованное мнение экспертов. Технологии живых систем. 2018;15(6):3-42.

292. Pan J, Garza F, Lyon AR. Cardio-oncology: rationale, aims and future directions. Curr Opin Support Palliat Care. 2021;15(2):134-40. doi:10.1097/SPC.0000000000000544.

293. Драпкина О. М., Брико Н. И., Костинов М. П. и др. Иммунизация взрослых. Методические рекомендации. М., ФГБУ "НМИЦ ТПМ" Минздрава России: 2020. 248 с.

294. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34. doi:10.18093/08690189-2019-29-1-19-34.

295. Иртюга О. Б., Шмаков Р. Г., Вавилова Т. В. и др. Дискуссионные вопросы применения антикоагулянтов в профилактике венозных тромбоэмболических осложнений у беременных с сердечно-сосудистыми и системными заболеваниями. Резолюция Совета экспертов. Российский кардиологический журнал. 2023;28(4):5421. doi:10.15829/1560-4071-2023-5421.

296. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/15604071-2023-5631.

297. Мацкеплишвили С. Т., Саидова М. А., Мироненко М. Ю. и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271. doi:10.15829/1560-40712025-6271. EDN: TNLDFN.

298. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-81.